Comparative analysis of the effects of aztreonam combined with four β-lactamase inhibitors against carbapenem-resistant Enterobacterales
Microbiology Spectrum · 2026
DOI: 10.1128/spectrum.01408-25 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Qing Meng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology Laboratory, Shenzhen Children's Hospital, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Aztreonam, Anti-Bacterial Agents, Carbapenem-Resistant Enterobacteriaceae. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties, Shenzhen Key Medical Discipline Construction Fund.
Abstract (Originalsprache)
Carbapenem-resistant Enterobacterales (CRE) pose a global public health threat due to multidrug resistance and treatment failure. This study evaluated the effects of aztreonam combined with four β-lactamase inhibitors (avibactam, clavulanic acid, tazobactam, and sulbactam) on 77 CRE isolates from Shenzhen Children’s Hospital. Among these isolates, 57.1% harbored metallo-β-lactamases (MBL) genes, and most co-harbored extended-spectrum β-lactamase (ESBL)/AmpC genes. Using microbroth dilution, checkerboard assays, and time‒kill curves, aztreonam/clavulanic acid showed potent synergy against MBL + /AmpC − strains (26/27), with MIC50/MIC90 values (≤0.12/1 µg/mL) comparable to those of aztreonam/avibactam (≤0.12/0.5 µg/mL). Aztreonam/tazobactam exhibited lower synergism, while aztreonam/sulbactam had indifferent effects. Time‒kill assays confirmed the similar bactericidal activity between aztreonam/clavulanic acid and aztreonam/avibactam against MBL + /ESBL + isolates. Although aztreonam/avibactam maintains broad efficacy, these in vitro studies suggest that the aztreonam/clavulanic acid combination regimen should be further explored as a potential and cost-effective alternative treatment option for MBL + /AmpC − CRE, which is expected to reduce the economic burden and delay avibactam resistance. These findings support tailored β-lactamase inhibitor selection on the basis of resistance mechanisms. IMPORTANCE Carbapenem-resistant Enterobacterales (CRE) pose significant risks for pediatric infections, with few safe and affordable therapeutic options available. This study focuses on a practical issue in current clinical research: aztreonam combined with clavulanic acid shows certain in vitro activity against CRE strains that carry metallo-β-lactamases gene but lack AmpC enzymes gene—a common profile among pediatric CRE isolates. Compared to the costly aztreonam/avibactam, this combination presents a potential low-cost candidate, which may help alleviate economic burdens on healthcare systems and patients if further validated. Additionally, the findings provide reference for reducing over-reliance on newer antibiotics like avibactam, supporting efforts to delay antimicrobial resistance. This work may be of practical use for regions with limited access to high-cost antimicrobials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Microbiology Laboratory, Shenzhen Children's Hospital, Shenzhen, Guangdong, China.
- First Clinical Medical College, Ningxia Medical University, Yinchuan, Ningxia, China.
- Department of Respiratory Diseases, Shenzhen Children's Hospital, Shenzhen, Guangdong, China.
- Department of Respiratory Medicine, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
- Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
ORCID-Profile: Qing Meng, Yunsheng Chen, Fupin Hu, Heping Wang
Förderung
- Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties
- Shenzhen Key Medical Discipline Construction Fund
Zitieren
APA
Meng, Q., Xu, C., Li, W., Shen, K., Huang, X., Fu, X., Zhou, L., Chen, Y., Hu, F., & Wang, H. (2026). Comparative analysis of the effects of aztreonam combined with four β-lactamase inhibitors against carbapenem-resistant Enterobacterales. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01408-25
Vancouver
Meng Q, Xu C, Li W, Shen K, Huang X, Fu X, et al. Comparative analysis of the effects of aztreonam combined with four β-lactamase inhibitors against carbapenem-resistant Enterobacterales. Microbiology Spectrum. 2026. doi:10.1128/spectrum.01408-25
BibTeX
@article{Meng2026,
author = {Meng, Qing and Xu, Chao and Li, Wujiao and Shen, Kunling and Huang, Xiuhui and Fu, Xiaoying and Zhou, Lintao and Chen, Yunsheng and Hu, Fupin and Wang, Heping},
title = {Comparative analysis of the effects of aztreonam combined with four β-lactamase inhibitors against carbapenem-resistant Enterobacterales},
journal = {Microbiology Spectrum},
year = {2026},
doi = {10.1128/spectrum.01408-25}
}
EUVIMED